Biomarin Pharmaceutical Inc. (BMRN) announced earnings for its second quarter that increased from the same period last year and beat the Street estimates.
The company's earnings totaled $107.174 million, or $0.55 per share. This compares with $56.040 million, or $0.29 per share, in last year's second quarter.
Excluding items, Biomarin Pharmaceutical Inc. reported adjusted earnings of $188.9 million or $0.96 per share for the period.
Analysts on average had expected the company to earn $0.35 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 19.6% to $712.029 million from $595.275 million last year.
Biomarin Pharmaceutical Inc. earnings at a glance (GAAP) :
-Earnings (Q2): $107.174 Mln. vs. $56.040 Mln. last year.-EPS (Q2): $0.55 vs. $0.29 last year.-Revenue (Q2): $712.029 Mln vs. $595.275 Mln last year.
-Guidance:Full year EPS guidance: $3.10 - $3.25Full year revenue guidance: $2,750 - $2,825 Mln
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.